7 results on '"Holz, Marina K."'
Search Results
2. Fanconi anemia and mTOR pathways functionally interact during stalled replication fork recovery.
- Author
-
Nolan M, Knudson K, Holz MK, and Chaudhury I
- Subjects
- Aphidicolin pharmacology, Cell Survival drug effects, DNA genetics, DNA metabolism, Fanconi Anemia metabolism, Fanconi Anemia pathology, Fanconi Anemia Complementation Group D2 Protein deficiency, Fibroblasts drug effects, Fibroblasts pathology, Genome, Human, Genomic Instability, Humans, Hydroxyurea pharmacology, Mitomycin pharmacology, Primary Cell Culture, Protein Binding drug effects, Signal Transduction, Sirolimus pharmacology, TOR Serine-Threonine Kinases metabolism, DNA Repair drug effects, DNA Replication drug effects, Fanconi Anemia genetics, Fanconi Anemia Complementation Group D2 Protein genetics, Fibroblasts metabolism, TOR Serine-Threonine Kinases genetics
- Abstract
We have previously demonstrated that Fanconi anemia (FA) proteins work in concert with other FA and non-FA proteins to mediate stalled replication fork restart. Previous studies suggest a connection between the FA protein FANCD2 and the non-FA protein mechanistic target of rapamycin (mTOR). A recent study showed that mTOR is involved in actin-dependent DNA replication fork restart, suggesting possible roles in the FA DNA repair pathway. In this study, we demonstrate that during replication stress mTOR interacts and cooperates with FANCD2 to provide cellular stability, mediate stalled replication fork restart, and prevent nucleolytic degradation of the nascent DNA strands. Taken together, this study unravels a novel functional cross-talk between two important mechanisms: mTOR and FA DNA repair pathways that ensure genomic stability., (© 2021 Federation of European Biochemical Societies.)
- Published
- 2021
- Full Text
- View/download PDF
3. Unraveling the multifaceted nature of the nuclear function of mTOR.
- Author
-
Torres AS and Holz MK
- Subjects
- Humans, Cell Nucleus metabolism, TOR Serine-Threonine Kinases metabolism
- Abstract
Positioned at the axis between the cell and its environment, mTOR directs a wide range of cellular activity in response to nutrients, growth factors, and stress. Our understanding of the role of mTOR is evolving beyond the spatial confines of the cytosol, and its role in the nucleus becoming ever more apparent. In this review, we will address various studies that explore the role of nuclear mTOR (nmTOR) in specific cellular programs and how these pathways influence one another. To understand the emerging roles of nuclear mTOR, we discuss data and propose plausible mechanisms to offer novel ideas, hypotheses, and future research directions., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation.
- Author
-
Alayev A, Berger SM, and Holz MK
- Subjects
- Animals, Antineoplastic Agents, Phytogenic therapeutic use, Humans, Molecular Targeted Therapy, Neoplasms drug therapy, Resveratrol, Stilbenes therapeutic use, Xenograft Model Antitumor Assays, Antineoplastic Agents, Phytogenic pharmacology, Neoplasms metabolism, Signal Transduction, Stilbenes pharmacology, TOR Serine-Threonine Kinases metabolism
- Abstract
The mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway is hyperactivated in a variety of cancers and tumor syndromes. Therefore, mTORC1 inhibitors are being actively investigated for treatment of neoplasms. The concern with the monotherapy use of mTORC1 inhibitors, such as rapamycin, is that they cause upregulation of autophagy, a cell survival mechanism, and suppress the negative feedback loop to the oncogene Akt. In turn, Akt promotes cell survival, causing the therapy to be partially effective, but relapse occurs upon cessation of treatment. In this review, we describe the current literature on resveratrol as well as our work, which uses rapamycin in combination with resveratrol. We found that this combination treatment efficiently blocked upregulation of autophagy and restored inhibition of Akt in different cancer and tumor models. Interestingly, the combination of rapamycin and resveratrol selectively promoted apoptosis of cells with mTOR pathway hyperactivation. Moreover, this combination prevented tumor growth and lung metastasis when tested in mouse models. Finally, mass spectrometry-based identification of cellular targets of resveratrol provided mechanistic insight into the mode of action of resveratrol. The addition of resveratrol to rapamycin treatment may be a promising option for selective and targeted therapy for diseases with mTORC1 hyperactivation., (© 2015 New York Academy of Sciences.)
- Published
- 2015
- Full Text
- View/download PDF
5. Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling.
- Author
-
Alayev A, Doubleday PF, Berger SM, Ballif BA, and Holz MK
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal pharmacology, Autophagy drug effects, Chromatography, Liquid, Culture Media, Serum-Free pharmacology, Humans, Immunoblotting, MCF-7 Cells, Mechanistic Target of Rapamycin Complex 1, Models, Biological, Phosphatidylinositol 3-Kinases metabolism, Phosphopeptides metabolism, Phosphorylation drug effects, Proteome metabolism, Resveratrol, Signal Transduction drug effects, Tandem Mass Spectrometry, Multiprotein Complexes metabolism, Phosphoproteins metabolism, Proteomics methods, Proto-Oncogene Proteins c-akt metabolism, Ribosomal Protein S6 Kinases, 70-kDa metabolism, Stilbenes pharmacology, TOR Serine-Threonine Kinases metabolism
- Abstract
Resveratrol, a plant-derived polyphenol, regulates many cellular processes, including cell proliferation, aging and autophagy. However, the molecular mechanisms of resveratrol action in cells are not completely understood. Intriguingly, resveratrol treatment of cells growing in nutrient-rich conditions induces autophagy, while acute resveratrol treatment of cells in a serum-deprived state inhibits autophagy. In this study, we performed a phosphoproteomic analysis after applying resveratrol to serum-starved cells with the goal of identifying the acute signaling events initiated by resveratrol in a serum-deprived state. We determined that resveratrol in serum-starved conditions reduces the phosphorylation of several proteins belonging to the mTORC1 signaling pathway, most significantly, PRAS40 at T246 and S183. Under these same conditions, we also found that resveratrol altered the phosphorylation of several proteins involved in various biological processes, most notably transcriptional modulators, represented by p53, FOXA1, and AATF. Together these data provide a more comprehensive view of both the spectrum of phosphoproteins upon which resveratrol acts as well as the potential mechanisms by which it inhibits autophagy in serum-deprived cells.
- Published
- 2014
- Full Text
- View/download PDF
6. mTOR signaling for biological control and cancer.
- Author
-
Alayev A and Holz MK
- Subjects
- Animals, Humans, Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Multiprotein Complexes antagonists & inhibitors, Multiprotein Complexes physiology, TOR Serine-Threonine Kinases antagonists & inhibitors, Neoplasms enzymology, Signal Transduction physiology, TOR Serine-Threonine Kinases physiology
- Abstract
Mammalian target of rapamycin (mTOR) is a major intersection that connects signals from the extracellular milieu to corresponding changes in intracellular processes. When abnormally regulated, the mTOR signaling pathway is implicated in a wide spectrum of cancers, neurological diseases, and proliferative disorders. Therefore, pharmacological agents that restore the regulatory balance of the mTOR pathway could be beneficial for a great number of diseases. This review summarizes current understanding of mTOR signaling and some unanswered questions in the field. We describe the composition of the mTOR complexes, upstream signals that activate mTOR, and physiological processes that mTOR regulates. We also discuss the role of mTOR and its downstream effectors in cancer, obesity and diabetes, and autism., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
7. The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells
- Author
-
Alayev, Anya, Berger, Sara Malka, Kramer, Melissa Y., Schwartz, Naomi S., and Holz, Marina K.
- Subjects
Sirolimus ,Ribosomal Protein S6 Kinases ,TOR Serine-Threonine Kinases ,Estrogen Receptor alpha ,Apoptosis ,Breast Neoplasms ,Drug Synergism ,Mechanistic Target of Rapamycin Complex 1 ,Models, Biological ,Article ,Up-Regulation ,Resveratrol ,Cell Line, Tumor ,Multiprotein Complexes ,Stilbenes ,Autophagy ,Humans ,Female ,biological phenomena, cell phenomena, and immunity ,Proto-Oncogene Proteins c-akt ,Cell Proliferation ,Signal Transduction - Abstract
Hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) is a frequent event in breast cancer and current efforts are aimed at targeting the mTORC1 signaling pathway in combination with other targeted therapies. However, patients often develop drug resistance in part due to activation of the oncogenic Akt signaling and upregulation of autophagy, which protects cancer cells from apoptosis. In the present study we investigated the effects of combination therapy of rapamycin (an allosteric mTORC1 inhibitor) together with resveratrol (a phytoestrogen that inhibits autophagy). Our results show that combination of these drugs maintains inhibition of mTORC1 signaling, while preventing upregulation of Akt activation and autophagy, causing apoptosis. Additionally, this combination was effective in estrogen receptor positive and negative breast cancer cells, underscoring its versatility.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.